LISTEN LIVE KPR - On Air: Listen Live to classical, jazz and NPR news Schedule LATEST
NEWSCAST
KPR 2 - On Air: Listen live to KPR's all talk-radio service, KPR2 Recordings

Share this page              

Powerful New Ebola Vaccine Heads To Congo To Help Stop Outbreak

A woman is vaccinated at a health center in Conakry, Guinea, during the clinical trials of a vaccine against the Ebola virus.

When Ebola erupted in West Africa a few years ago, it was catastrophic.

But one good thing emerged from the outbreak: The development of an Ebola vaccine — a powerful vaccine.

As we reported back in December, the vaccine provided 100 percent protection against Ebola when given quickly after exposure.

"It's very unusual to have a vaccine that protects people perfectly," said Ira Longini, a biostatistician at the University of Florida, who helped test the vaccine.

Now that vaccine is headed to the Democratic Republic of Congo to help fight a small outbreak there. Since late April, Congo has reported about 19 cases, the World Health Organization said.

On Monday, the Congo government agreed to use the vaccine.

"Now there's a Medecins Sans Frontiers team that is arriving [in Congo] today to validate the protocol with the technical teams," Jonathan Simba, a health ministry spokesman, told Reuters.

The outbreak already shows signs of slowing down. There hasn't been a new confirmed case since May 11. And several suspected cases were ruled out last week.

Congo has a long history fighting Ebola. Since the virus was first detected there in 1976, the country has reported seven other outbreaks. In all instances, health workers have stopped the disease by isolating infected people. This is the first outbreak since the vaccine became available.

The vaccine — called rVSV-ZEBOV — took about two decades to develop. Scientists in the U.S. and Canada started working on it back in the 1990s and early 2000s. Then it sat on the shelf for years because of lack of funding.

Toward the end of the outbreak in West Africa, scientists began testing the vaccine in a large trial with more than 4,000 people. The shot worked extremely well and had mild side effects, such as headache and muscle pain.

The vaccine hasn't been approved yet by either the World Health Organization or the U.S. Food and Drug Administration. That's predicted to happen sometime in 2018.

But GAVI — the Global Alliance for Vaccines and Immunization — has already spent $5 million to help finish the development and manufacturing of the vaccine, in partnership with the pharmaceutical company Merck.

Together, they have stockpiled 300,000 doses of the vaccine. Now the challenge is getting the shot to a remote corner of Congo.


Copyright 2017 NPR. To see more, visit http://www.npr.org/.

Tower Frequencies

91.5 FM KANU Lawrence, Topeka, Kansas City
96.1 FM K241AR Lawrence (KPR2)
89.7 FM KANH Emporia
99.5 FM K258BT Manhattan
97.9 FM K250AY Manhattan (KPR2)
91.3 FM  KANV Junction City, Olsburg
89.9 FM K210CR Atchison
90.3 FM KANQ Chanute

See the Coverage Map for more details

Contact Us

Kansas Public Radio
1120 West 11th Street
Lawrence, KS 66044
Download Map
785-864-4530 (Main Line)
888-577-5268 (Toll Free)
contact@kansaspublicradio.org